E. David Crawford

Jan 23, 2025 | renalandurologynews.com | E. David Crawford

As a urologist with over 30 years of experience in prostate cancer care, I’ve seen incredible advancements in our understanding of the disease. Among these, precision medicine tools, particularly biomarker tests, have transformed our approach to personalized care. However, despite their proven benefits, biomarker tests remain underused in clinical practice—a missed opportunity for enhancing patient outcomes.

Apr 22, 2024 | europeanurology.com | Fred Saad |E. David Crawford |Luke T Nordquist |Maha Hussain |Bertrand Tombal |Karim Fizazi | +10 more

AbstractAddition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel.